☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Rosiglitazone increases CV events

The New England Journal of Medicine has published the results of a meta-analysis examining the cardiovascular safety of rosiglitazone as an online first article. There is currently free access to full text and PDF versions of the paper.

The study included analysis of 42 papers including data for almost 28,000 patients. Data were collected for outcomes of myocardial infarction and death from cardiovascular causes.

Due to limitations in the published data it was not possible to calculate hazard ratios, however there was a statistically increased risk of myocardial infarction (Odds ratio 1.43, 95% confidence interval [CI], 1.03 to 1.98; P=0.03) and a non significant increase in the risk of cardiovascular death (Odds ratio 1.64, 95% CI, 0.98 to 2.74; P=0.06).

Despite the limitations imposed by a lack of access to original source data the authors of this analysis conclude that clinicians "should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone".

Pioglitazone was not studied in this analysis. The PROactive study did contain a secondary endpoint showing some cardiovascular benefit. However, since the primary endpoint in that study did not reach statistical significance the validity of this benefit has been questioned.

Action: Metformin remains the first line hypoglycaemic in all patients with type 2 diabetes. Once the symptoms of diabetes are relieved treatment should focus upon lowering blood pressure and cardiovascular risk, not on lowering blood glucose. Pioglitazone or a sulphonylurea may be suitable choices if additional hypoglycaemic agents are deemed necessary.

Share 'Rosiglitazone increases CV events' by emailShare 'Rosiglitazone increases CV events' on FacebookShare 'Rosiglitazone increases CV events' on TwitterShare 'Rosiglitazone increases CV events' on LinkedInShare 'Rosiglitazone increases CV events' on reddit


4 Comments to “Rosiglitazone increases CV events”

  1. [...] known. Glitazones increase the risk of heart failure and fractures. Rosiglitazone has also been suspected of increasing the risk of heart attacks and while this study indicates no increased risk of [...]

    Pingback by Prescribing Advice for GPs » New RECORD but same tune — June 22, 2009 #

  2. Blood Pressure and Weight Loss

    Over weight is a common cause to a number of problems. There are a number of people who are facing the problem of over weight and obesity.

    Trackback by Increases In Blood Pressure — February 4, 2008 #

  3. [...] Over the past month the New England Journal of Medicine has published a meta-analysis and an interim results paper of the RECORD study concerned with the cardiovascular safety of rosiglitazone. There is coverage of both the meta-analysis and the trial data at prescriber.org.uk. [...]

    Pingback by adr.org.uk » Blog Archive » Rosiglitazone (Avandia) and cardiovascular events — June 20, 2007 #

  4. GSK - Avandia: MHRA advise patients

    Trackback by Trusted.MD Network — May 24, 2007 #

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.